Tirzepatide + Vitamin B6 — Compounded for Individual Biology

Administered by subcutaneous injection once weekly. Inject into the abdomen, thigh, or upper arm. Rotate injection sites with each dose. Inspect the solution before use—it should be clear and colorless to slightly yellow; discard if cloudy, discolored, or particulate matter is present. Do not inject into the same location used the prior week.

Tirzepatide is initiated at a low dose and titrated upward based on tolerability and therapeutic response. A typical escalation schedule follows the established clinical pattern:

• Starting dose: 2.5 mg subcutaneously once weekly (for treatment initiation; not intended for therapeutic effect)
• After 4 weeks: increase to 5 mg once weekly
• If additional response is needed: increase in 2.5 mg increments every 4 or more weeks
• Maintenance doses: 5–15 mg once weekly (maximum 15 mg/week)

The B6 dose is prescriber-determined. Final tirzepatide dose, titration pace, and B6 strength are individualized by the prescriber.

• Tirzepatide: A 39-amino-acid synthetic peptide that acts as a co-agonist at both GIP receptors and GLP-1 receptors. GLP-1 receptor activation enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion from alpha cells, delays gastric emptying, and reduces food intake via central appetite regulation. GIP receptor activation amplifies insulin secretion synergistically and may further modulate adipose tissue metabolism. The dual incretin mechanism produces greater glycemic and weight reductions than selective GLP-1 agonists alone.
• Pyridoxine (Vitamin B6): Serves as a cofactor in neurotransmitter synthesis (serotonin, GABA, dopamine) and amino acid metabolism. Its antiemetic mechanism is not fully elucidated but is thought to involve modulation of serotonergic pathways in the chemoreceptor trigger zone, reducing nausea signals.

Tirzepatide with B6 is used prescriber-directed for type 2 diabetes mellitus management and/or chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The inclusion of B6 is intended to support tolerability during dose escalation, when nausea is most prevalent.

Monitoring parameters:

• HbA1c every 3 months until at goal, then every 6 months
• Fasting blood glucose periodically; assess for hypoglycemia risk if on concurrent insulin or sulfonylureas
• Body weight and BMI
• Renal function if GI adverse effects (nausea, vomiting, diarrhea) are severe
• Amylase/lipase if symptoms of pancreatitis occur (abdominal pain, nausea, vomiting)
• Thyroid ultrasound in patients with a palpable thyroid nodule

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to tirzepatide or any excipient

Warnings & Precautions:

• Thyroid C-cell tumors: rodent studies showed dose-dependent thyroid C-cell neoplasms; clinical relevance unknown but contraindicated in MTC/MEN2 personal/family history
• Pancreatitis: discontinue if pancreatitis is suspected; not recommended in patients with history of pancreatitis
• Hypoglycemia: risk is elevated when combined with insulin or sulfonylureas; dose reduction of those agents may be needed
• Gastrointestinal adverse effects: nausea, vomiting, diarrhea, constipation are common, particularly during initiation and escalation
• Acute kidney injury secondary to dehydration from GI adverse effects
• Diabetic retinopathy worsening: rapid improvement in glycemic control may transiently worsen retinopathy
• Heart rate increase: modest increases in resting heart rate have been observed

Drug Interactions:

• Insulin and insulin secretagogues: increased hypoglycemia risk; reduce their doses
• Oral medications: delayed gastric emptying may alter absorption of oral drugs; monitor narrow therapeutic index drugs

Common Side Effects: Nausea (most common), vomiting, diarrhea, constipation, decreased appetite, injection site reactions, and fatigue.

Store the compounded injectable refrigerated at 2–8°C (36–46°F). Protect from light; do not freeze. Once removed from refrigeration, may be kept at room temperature (up to 30°C) for a short period as specified by Genesis Compounding's BUD labeling. Discard any unused solution after the beyond-use date. Do not use if the solution is cloudy or contains particulates.

Why is Vitamin B6 added to tirzepatide?

Nausea is the most common side effect of tirzepatide, especially during the first weeks of treatment and with dose increases. Pyridoxine (Vitamin B6) is an established antiemetic adjunct—it is used clinically for pregnancy-related nausea—and is included to improve tolerability and support adherence during dose escalation.

How is this medication given?

Subcutaneous injection once weekly into the abdomen, thigh, or upper arm. Rotate the injection site each week.

Is this FDA-approved?

Tirzepatide (Mounjaro® for T2DM; Zepbound® for obesity) is FDA-approved as a branded single-agent product. This compounded combination with Vitamin B6 is a 503A patient-specific preparation by Genesis Compounding and is not FDA-approved as a compounded product.

What if I miss a dose?

If fewer than 4 days (96 hours) have passed since the missed dose, inject it as soon as remembered and resume the regular weekly schedule. If more than 4 days have passed, skip the missed dose and continue on the normal schedule.

What GI symptoms are expected and when do they improve?

Nausea, mild vomiting, and changes in bowel habits are common, especially during the first 4–8 weeks and after each dose increase. These effects typically diminish as the body adjusts. The B6 component is intended to reduce the severity of nausea.